79 related articles for article (PubMed ID: 22753703)
1. Therapeutic potential of tranilast, an anti-allergy drug, in proliferative disorders.
Rogosnitzky M; Danks R; Kardash E
Anticancer Res; 2012 Jul; 32(7):2471-8. PubMed ID: 22753703
[TBL] [Abstract][Full Text] [Related]
2. Tranilast treatment decreases cell growth, migration and inhibits colony formation of human breast cancer cells.
Subramaniam V; Ace O; Prud'homme GJ; Jothy S
Exp Mol Pathol; 2011 Feb; 90(1):116-22. PubMed ID: 21040720
[TBL] [Abstract][Full Text] [Related]
3. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
[TBL] [Abstract][Full Text] [Related]
4. Tranilast: a review of its therapeutic applications.
Darakhshan S; Pour AB
Pharmacol Res; 2015 Jan; 91():15-28. PubMed ID: 25447595
[TBL] [Abstract][Full Text] [Related]
5. Tranilast inhibits the growth and metastasis of mammary carcinoma.
Chakrabarti R; Subramaniam V; Abdalla S; Jothy S; Prud'homme GJ
Anticancer Drugs; 2009 Jun; 20(5):334-45. PubMed ID: 19322072
[TBL] [Abstract][Full Text] [Related]
6. Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10.
Hertenstein A; Schumacher T; Litzenburger U; Opitz CA; Falk CS; Serafini T; Wick W; Platten M
Biochem Pharmacol; 2011 Sep; 82(6):632-41. PubMed ID: 21703247
[TBL] [Abstract][Full Text] [Related]
7. Tranilast inhibits cell proliferation and collagen synthesis by rabbit corneal and Tenon's capsule fibroblasts.
Oshima T; Kurosaka D; Kato K; Kurosaka H; Mashima Y; Tanaka Y; Tajima S
Curr Eye Res; 2000 Apr; 20(4):283-6. PubMed ID: 10806442
[TBL] [Abstract][Full Text] [Related]
8. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon-gamma (IFN-gamma).
Platten M; Wick W; Wischhusen J; Weller M
Br J Pharmacol; 2001 Nov; 134(6):1279-84. PubMed ID: 11704648
[TBL] [Abstract][Full Text] [Related]
9. Inhibition by tranilast of the cytokine-induced expression of chemokines and the adhesion molecule VCAM-1 in human corneal fibroblasts.
Adachi T; Fukuda K; Kondo Y; Nishida T
Invest Ophthalmol Vis Sci; 2010 Aug; 51(8):3954-60. PubMed ID: 20335611
[TBL] [Abstract][Full Text] [Related]
10. Suppressive effects of tranilast on eotaxin-1 production from cultured conjunctival fibroblasts.
Hida RY; Takano Y; Okada N; Dogru M; Satake Y; Fukagawa K; Fujishima H
Curr Eye Res; 2008 Jan; 33(1):19-22. PubMed ID: 18214739
[TBL] [Abstract][Full Text] [Related]
11. Effects of tranilast and pentoxifylline in a mouse model of chronic asthma using house dust mite antigen.
Kim SJ; Kim JW; Kim YH; Lee SH; Yoon HK; Kim CH; Ahn JH; Lee JM; Kim JS; Kim SC; Lee SY; Kwon SS; Kim YK
J Asthma; 2009 Nov; 46(9):884-94. PubMed ID: 19905913
[TBL] [Abstract][Full Text] [Related]
12. Tranilast ameliorates renal tubular damage in unilateral ureteral obstruction.
Miyajima A; Asano T; Asano T; Yoshimura I; Seta K; Hayakawa M
J Urol; 2001 May; 165(5):1714-8. PubMed ID: 11342962
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional activation of p21 by Tranilast is mediated via transforming growth factor beta signal pathway.
Charng MJ; Wu CH
Br J Pharmacol; 2006 Jan; 147(1):117-24. PubMed ID: 16284627
[TBL] [Abstract][Full Text] [Related]
14. Uncontrollable prurigo nodularis effectively treated by roxithromycin and tranilast.
Horiuchi Y; Bae S; Katayama I
J Drugs Dermatol; 2006 Apr; 5(4):363-5. PubMed ID: 16673805
[TBL] [Abstract][Full Text] [Related]
15. Use of Tranilast [N-(3,4-dimethoxycinnamoyl) anthranilic acid] in secretory otitis media.
Ogino S; Harada T; Matsunaga T; Tominaga Y
Ann Allergy; 1992 May; 68(5):407-12. PubMed ID: 1375005
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of tranilast on proliferation, migration, and collagen synthesis of human vascular smooth muscle cells.
Fukuyama J; Miyazawa K; Hamano S; Ujiie A
Can J Physiol Pharmacol; 1996 Jan; 74(1):80-4. PubMed ID: 8963955
[TBL] [Abstract][Full Text] [Related]
17. Preliminary results of tranilast treatment for patients with advanced castration-resistant prostate cancer.
Izumi K; Mizokami A; Shima T; Narimoto K; Sugimoto K; Kobori Y; Maeda Y; Konaka H; Koh E; Namiki M
Anticancer Res; 2010 Jul; 30(7):3077-81. PubMed ID: 20683058
[TBL] [Abstract][Full Text] [Related]
18. Effects of topical tranilast on corneal haze after photorefractive keratectomy.
Song JS; Jung HR; Kim HM
J Cataract Refract Surg; 2005 May; 31(5):1065-73. PubMed ID: 15975479
[TBL] [Abstract][Full Text] [Related]
19. Effect of tranilast on matrix metalloproteinase production from neutrophils in-vitro.
Shimizu T; Kanai K; Kyo Y; Asano K; Hisamitsu T; Suzaki H
J Pharm Pharmacol; 2006 Jan; 58(1):91-9. PubMed ID: 16393468
[TBL] [Abstract][Full Text] [Related]
20. Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model.
Kelly DJ; Zhang Y; Gow R; Gilbert RE
J Am Soc Nephrol; 2004 Oct; 15(10):2619-29. PubMed ID: 15466266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
